Welcome to our dedicated page for Ionis Pharmaceuticals news (Ticker: IONS), a resource for investors and traders seeking the latest updates and insights on Ionis Pharmaceuticals stock.
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) is a leading biotechnology company headquartered in Carlsbad, California. Founded in 1989, Ionis has been pioneering the discovery and development of antisense drugs, with an impressive portfolio of over 1300 patents. Ionis focuses on creating innovative RNA-targeted therapies for complex diseases, particularly in the areas of cardiovascular, metabolic, neurological, and rare genetic disorders.
Ionis has successfully brought several groundbreaking medicines to market. Notable achievements include the development of Spinraza, in collaboration with Biogen, which was launched in 2016 to treat spinal muscular atrophy, a rare neuromuscular disorder. In 2023, Biogen also launched Qalsody for ALS, further extending the impact of Ionis' antisense technology.
Through its cardiovascular-focused subsidiary, Akcea Therapeutics, Ionis has introduced drugs like Tegsedi for ATTR amyloidosis and Waylivra in Europe for cardiology indications. The company continues to advance its pipeline with promising candidates such as olezarsen, an investigational RNA-targeted therapy for familial chylomicronemia syndrome (FCS). Ionis' ongoing Phase 3 trials for olezarsen have shown promising results, with significant reductions in triglyceride levels and improvements in related health outcomes.
Ionis' commitment to innovation and patient care is also evident in its robust financial health and strategic partnerships. With a deep understanding of disease biology and cutting-edge technology, Ionis continues to drive advancements in RNA therapies and gene editing, aiming to deliver life-changing medicines for patients around the world.
Recently, Ionis announced positive clinical trial results for several of its investigational drugs and plans to pursue regulatory approvals for these therapies. The company's pipeline is well-positioned to address unmet medical needs in various therapeutic areas, promising a steady flow of new treatments in the coming years.
For more detailed information about Ionis Pharmaceuticals, its products, and career opportunities, visit their official website at www.ionispharma.com.
Akcea Therapeutics (NASDAQ: AKCA) and Ionis Pharmaceuticals (NASDAQ: IONS) announced positive results from the Phase 2 study of AKCEA-APOCIII-LRx, presented at the ESC Congress 2020. The study demonstrated significant reductions in triglyceride levels (TG) and apoC-III, with a notable 62% reduction in TG at the highest dose administered. Furthermore, 91% of patients achieved TG levels below 150 mg/dL at six months. The drug exhibited a favorable safety profile, with plans for a Phase 3 trial targeting familial chylomicronemia syndrome (FCS) later this year.
Ionis Pharmaceuticals will host a live webcast on September 2 at 10:00 a.m. ET to discuss its cardio-renal franchise. The 90-minute session will feature presentations from its executives, including Brett P. Monia and Sam Tsimikas. Key topics will include advances in RNA-targeted drug discovery and specific medicines aimed at treating triglyceride-driven diseases, thrombosis, and treatment-resistant hypertension. The webcast can be accessed at www.ionispharma.com.
On August 24, 2020, Akcea Therapeutics and Ionis Pharmaceuticals announced that data from the Phase 2 clinical trial of vupanorsen (AKCEA-ANGPTL3-LRx) will be presented at the ESC Congress 2020, scheduled for August 29-September 1, 2020. Vupanorsen is an investigational therapy targeting cardiovascular diseases by reducing ANGPTL3 protein levels in patients with conditions such as hypertriglyceridemia and type 2 diabetes. The companies previously secured a $250 million licensing deal with Pfizer, which will assume further development responsibilities.
Akcea Therapeutics and Ionis Pharmaceuticals announced that data from the Phase 2 study of AKCEA-APOCIII-LRx will be presented at the ESC Congress 2020 from August 29 to September 1, 2020. The drug aims to reduce apolipoprotein C-III levels, a protein linked to triglyceride regulation and cardiovascular risk. Previous studies showed promising results, with dose-dependent reductions in triglycerides and increases in HDL-C. This presentation may influence the drug's market potential and investor outlook.
Akcea Therapeutics has announced new pricing and reimbursement terms for WAYLIVRA® (volanesorsen) in Germany, effective August 15, 2020. This renegotiation, required 12 months post-commercialization, highlights the drug's value for patients with familial chylomicronemia syndrome (FCS) at high risk for pancreatitis. WAYLIVRA is now the only therapy approved for FCS in the EU, following its launch in August 2019. Akcea aims to expand WAYLIVRA's availability to more European countries, supporting the needs of patients suffering from this ultra-rare disease.
Ionis Pharmaceuticals reported Q2 2020 results, achieving a non-GAAP net income of $8 million despite a GAAP net loss of $32 million. Revenue rose to $146 million, driven by $72 million in SPINRAZA royalties and increased product sales. Ionis maintains its 2020 financial guidance, targeting profitability. The company has over $2.3 billion in cash, supporting future initiatives. Progress includes advancements in neurological and cardio-renal programs, with expectations for multiple marketing applications through 2025. Key studies for new treatments are set to begin, enhancing growth potential.
Ionis Pharmaceuticals (NASDAQ: IONS) will host a live webcast on August 5, 2020 at 11:30 a.m. ET to discuss its Q2 2020 financial results and provide updates on its pipeline and business progress. This event will focus on the company's advancements in RNA-targeted drug discovery, highlighting their innovative antisense technology that addresses unmet medical needs.
Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, will host a live webcast on August 4, 2020, at 4:30 p.m. ET to discuss its Q2 2020 financial results and pipeline progress. The company's medicines, including TEGSEDI and WAYLIVRA, target serious and rare diseases. With a robust pipeline, Akcea is poised for future growth in the biopharmaceutical sector.
Investors can access the webcast at this link.
Akcea Therapeutics (NASDAQ: AKCA) announces the appointment of Christophe Hotermans, M.D., Ph.D., as senior vice president of global medical affairs. With over 20 years of experience, including a decade at Biogen, Dr. Hotermans will lead the company's medical strategies and operations worldwide. His expertise in specialty care and rare diseases aligns with Akcea's goals, focusing on the commercial launch of TEGSEDI and WAYLIVRA. Akcea, a majority-owned affiliate of Ionis Pharmaceuticals (NASDAQ: IONS), continues to develop medicines for serious and rare diseases, supported by a strong pipeline.
Ionis Pharmaceuticals (NASDAQ: IONS) will host a live webcast on July 14, 2020, at 10:00 a.m. Eastern Time to discuss its neurology franchise. The presentation will feature key executives, including CEO Brett P. Monia and Chief Scientific Officer Frank Bennett, covering various neurological diseases like Amyotrophic Lateral Sclerosis, Alzheimer's, Parkinson's, and more. Participants can access the webcast through Ionis' website, where a replay will also be available.
Ionis is recognized for its leadership in RNA-targeted therapeutics.
FAQ
What is the current stock price of Ionis Pharmaceuticals (IONS)?
What is the market cap of Ionis Pharmaceuticals (IONS)?
What does Ionis Pharmaceuticals specialize in?
Where is Ionis Pharmaceuticals located?
What are some key products developed by Ionis Pharmaceuticals?
What is the latest development in Ionis' pipeline?
Who are some of Ionis' key partners?
How does Ionis Pharmaceuticals contribute to RNA therapy innovation?
What is olezarsen and what does it treat?
How can I learn more about career opportunities at Ionis Pharmaceuticals?
What recent clinical trials has Ionis Pharmaceuticals announced?
How does Ionis Pharmaceuticals support patients with rare diseases?
